Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer Chemotherapy

30 Dec 2003

Abstract excerpt

The seminal discoveries of camptothecin and Taxol by Wall and Wani are discussed in a manner that demonstrates the influence that these two compounds has had on the further development of natural product, natural product-derived, and (some) synthetic entities as potential drug leads that interact either with tubulin or with topoisomerase I. The major categories of tubulin interactive agents in terms of inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioactive Compounds and Antitumor Agents
Share to Cancer therapeutics and mechanisms
Share to Cancer Treatment and Pharmacology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 14987065
DOI: 10.1021/np030420c

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer ChemotherapyPMID 14987065Read ↗

Tubulin-Interactive Natural Products as Anticancer AgentsSemantic proximity Read ↗

Novel camptothecin derivatives as topoisomerase I inhibitorsSemantic proximity Read ↗

A review of research progress of antitumor drugs based on tubulin targetsSemantic proximity Read ↗

A patent review of topoisomerase I inhibitors (2016–present)Semantic proximity Read ↗

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceSemantic proximity Read ↗

Microtubule-Stabilizing Natural Products as Promising Cancer TherapeuticsSemantic proximity Read ↗

Targeting Microtubules by Natural Agents for Cancer TherapySemantic proximity Read ↗

The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance MechanismsSemantic proximity Read ↗

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.Semantic proximity Read ↗

Recent developments in topoisomerase-targeted cancer chemotherapySemantic proximity Read ↗

Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical TrialsSemantic proximity Read ↗

Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.